Leerink Partnrs Issues Pessimistic Outlook for ITOS Earnings

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Analysts at Leerink Partnrs dropped their Q2 2025 earnings per share estimates for iTeos Therapeutics in a report issued on Wednesday, May 28th. Leerink Partnrs analyst D. Graybosch now forecasts that the company will post earnings of ($0.84) per share for the quarter, down from their previous estimate of ($0.62). Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for iTeos Therapeutics' current full-year earnings is ($3.49) per share. Leerink Partnrs also issued estimates for iTeos Therapeutics' Q3 2025 earnings at ($0.67) EPS and FY2025 earnings at ($2.31) EPS.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last announced its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, beating analysts' consensus estimates of ($0.94) by $0.14.

ITOS has been the subject of several other reports. Raymond James set a $12.00 price objective on iTeos Therapeutics in a research report on Wednesday, May 14th. JPMorgan Chase & Co. downgraded iTeos Therapeutics from an "overweight" rating to a "neutral" rating and cut their price objective for the stock from $15.00 to $8.00 in a research report on Tuesday, May 13th. Leerink Partners restated a "market perform" rating and set a $9.00 price objective (down from $47.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Piper Sandler restated an "overweight" rating and set a $12.00 price objective (down from $16.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Finally, Wells Fargo & Company restated an "equal weight" rating and set a $12.00 price objective (down from $13.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 28th. Six analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $15.86.

iTeos Therapeutics Trading Down 0.1%

Shares of ITOS stock traded down $0.01 during mid-day trading on Monday, reaching $10.01. The stock had a trading volume of 1,382,098 shares, compared to its average volume of 647,334. iTeos Therapeutics has a 12-month low of $4.80 and a 12-month high of $18.13. The company has a market cap of $383.12 million, a P/E ratio of -3.18 and a beta of 1.39. The business has a 50-day simple moving average of $6.99 and a 200 day simple moving average of $7.39.

Institutional Trading of iTeos Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Strs Ohio purchased a new stake in iTeos Therapeutics during the 1st quarter worth $31,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in iTeos Therapeutics during the 4th quarter worth $42,000. CWM LLC boosted its position in iTeos Therapeutics by 428.7% during the 1st quarter. CWM LLC now owns 8,554 shares of the company's stock worth $51,000 after purchasing an additional 6,936 shares during the period. Paloma Partners Management Co purchased a new stake in iTeos Therapeutics during the 1st quarter worth $65,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in iTeos Therapeutics during the 1st quarter worth $67,000. 97.16% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the business's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $5,079,339.46. Following the completion of the sale, the insider now directly owns 2,108,594 shares of the company's stock, valued at $16,995,267.64. The trade was a 23.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Ansbert Gadicke sold 1,031,931 shares of the business's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the sale, the insider now directly owns 3,452,797 shares of the company's stock, valued at $27,829,543.82. This represents a 23.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 12.50% of the stock is owned by corporate insiders.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.